{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T22:58:59Z","timestamp":1770677939756,"version":"3.49.0"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"vor","delay-in-days":5783,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["aao-hnsfjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngol.--head neck surg."],"published-print":{"date-parts":[[2000,11]]},"abstract":"<jats:p>Otic drops of either ciprofloxacin 0.2% solution (CIP) or a combination of polymyxin B, neomycin, and hydrocortisone suspension (PNH) were administered for 6 to 12\u00a0days to patients (14\u201071 years old) with chronic suppurative otitis media in a randomized, nonblinded, multicenter clinical trial. Two hundred thirty\u2010two enrolled patients were analyzed for efficacy on a \u201cper protocol\u201d basis. The most frequently identified causal agents were <jats:italic>Staphylococcus aureus<\/jats:italic> (28% of the patients), <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (19%), and <jats:italic>Staphylococcus<\/jats:italic> sp (9%). Clinical success was observed in 91% and 87% of the CIP\u2010and PNH\u2010treated patients, respectively. At 1\u2010month follow\u2010up, 4% of CIP and 6% of PNH patients showed a relapse of otorrhea. Bacteriologic eradication was seen in 89% and 85% of patients in the CIP and PNH groups, respectively. At 1\u2010month follow\u2010up, reinfection or recurrence of infection appeared in 3 patients in the PNH group and in 1 patient in the CIP group. Both treatments were well tolerated. The most frequently reported adverse events were pruritus, stinging, and earache. Audiometric tests did not show changes attributable to study drugs in any but 1 patient in the PNH group. This clinical trial shows that topical 0.2% ciprofloxacin solution in single\u2010dose containers is effective and well tolerated in patients with chronic suppurative otitis media.<\/jats:p>","DOI":"10.1067\/mhn.2000.107888","type":"journal-article","created":{"date-parts":[[2003,2,4]],"date-time":"2003-02-04T21:49:09Z","timestamp":1044395349000},"page":"617-623","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Controlled Multicenter Study on Chronic Suppurative Otitis Media Treated with Topical Applications of Ciprofloxacin 0.2% Solution in Single\u2010Dose Containers or Combination of Polymyxin B, Neomycin, and Hydrocortisone Suspension"],"prefix":"10.1002","volume":"123","author":[{"given":"Nuria","family":"Mir\u00f3","sequence":"first","affiliation":[{"name":"Servicio de Otorrinolaringolog\u00eda Hospital Universitario Germans Trias i Pujol Badalona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Spanish Ent Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,9]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)30388-1"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402800915"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1992.01880040050009"},{"key":"e_1_2_11_5_2","first-page":"141","article-title":"Ototoxicity and ototopical medications: A survey of otolaryngologists","volume":"14","author":"Lundy LB","year":"1993","journal-title":"Am J Otol"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0194-59989770212-2"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000239314"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000239312"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199300453-00126"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.3.452"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.5.1014"},{"key":"e_1_2_11_12_2","first-page":"175","article-title":"Ototoxicity of gyrase antagonist ciprofloxacin?","volume":"45","author":"Lutz H","year":"1990","journal-title":"Adv Otorhinolaryngol"},{"key":"e_1_2_11_13_2","first-page":"521","article-title":"Estudio multic\u00e9ntrico comparativo de la eficacia y tolerancia de ciprofloxacino t\u00f3pico (0,3%) versus gentamicina t\u00f3pica (0,3%) en el tratamiento de la otitis media cr\u00f3nica simple no colesteatomatosa en fase supurativa","author":"Lorente J","year":"1995","journal-title":"Ann Iber\u2010Amer"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1995.01890080048009"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0194-59989770293-6"},{"key":"e_1_2_11_16_2","volume-title":"Ear preparations (1997:0652)","year":"1997"},{"key":"e_1_2_11_17_2","unstructured":"Committee for Proprietary Medicinal Products. Note for guidance on evaluation of new anti\u2010bacterial medicinal products. CPMP\/EWP\/558\/95.April 1997."},{"key":"e_1_2_11_18_2","volume-title":"Statistical tables for the design of clinical trials","author":"Machin D","year":"1987"},{"key":"e_1_2_11_19_2","volume-title":"Treatment of chronic suppurative otitis media (Cochrane review)","author":"Acuin J","year":"1999"},{"key":"e_1_2_11_20_2","first-page":"413","article-title":"Bakterielle Otitis externa mit \u00fcberschreitung der Organgrenzen\u2014systemische und lokale Kombinations\u2010behandlung mit Ciprofloxacin","volume":"87","author":"Ganz H.","year":"1993","journal-title":"Z Artzl Fortbild"},{"key":"e_1_2_11_21_2","first-page":"67","article-title":"Lokale behandeling van otitis media en otitis externa: Rol van de quinolones","volume":"48","author":"De Schepper S","year":"1994","journal-title":"Acta Otorhinolaryngol Belg"}],"container-title":["Otolaryngology\u2013Head and Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1067\/mhn.2000.107888","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1067\/mhn.2000.107888","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1067\/mhn.2000.107888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:56:50Z","timestamp":1760965010000},"score":1,"resource":{"primary":{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/10.1067\/mhn.2000.107888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["10.1067\/mhn.2000.107888"],"URL":"https:\/\/doi.org\/10.1067\/mhn.2000.107888","archive":["Portico"],"relation":{},"ISSN":["0194-5998","1097-6817"],"issn-type":[{"value":"0194-5998","type":"print"},{"value":"1097-6817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11]]},"assertion":[{"value":"2016-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}